Post-approval studies (Phase 4)Not Yet RecruitingNCT07668570
What this trial is testing
SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma
Who this might be right for
HCC - Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital 36